Bristol Myers Squibb’s arlo-cel clears pivotal myeloma endpoints after BCMA therapy
Arlocabtagene autoleucel met response and complete-response endpoints in patients already exposed to immunomodulators, proteasome inhibitors, anti-CD38 treatment and BCMA therapy, positioning GPRC5D as a possible next CAR T target after increasingly crowded myeloma treatment sequences.